The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1609
ISSUE 1609
October 19, 2020
Lyumjev - A New Insulin Lispro for Diabetes
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
October 19, 2020 (Issue: 1609)
The FDA has approved insulin lispro-aabc (Lyumjev –
Lilly), a faster-acting formulation of insulin lispro
(Humalog), for treatment of type 1 and type 2 diabetes
in adults. Fiasp, a faster-acting formulation of insulin
aspart (Novolog), was approved in 2017.
... more
- Fiasp—another insulin aspart formulation for diabetes. Med Lett Drugs Ther 2018; 60:6.
- In brief: Another insulin lispro (Admelog) for diabetes. Med Lett Drugs Ther 2018; 60:e109.
- J Leohr et al. A novel insulin lispro formulation containing citrate and trepostinil demonstrates faster absorption and onset of action in healthy subjects. Diabetes 2017; 66(Suppl1): A253. Abstract 976-P.
- T Heise et al. Ultrarapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study. Diabetes Obes Metab 2020 May 21 (epub).
- L Klaff et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab 2020 June 2 (epub).
- T Blevins et al. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care 2020 July 2 (epub).
- Insulins for type 2 diabetes. Med Lett Drugs Ther 2019; 61:65.
- American Diabetes Association. Introduction: standards of medical care in diabetes – 2020. Diabetes Care 2020; 43(Suppl1):S1.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Lyumjev - A New Insulin Lispro for Diabetes
Article code: 1609b
Electronic, downloadable article - $45
Article code: 1609b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian